Early Development Led by the PCCTC, FDA Approval Now Sought for Apalutamide

Media Relations by Jason Harris - OncLive October 12, 2017

A new drug application (NDA) has been submitted to the FDA for apalutamide (ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.